Pacira BioSciences (PCRX) Operating Leases (2019 - 2026)

Pacira BioSciences' Operating Leases history runs 8 years deep, the most recent figure standing at $33.7 million for Q1 2026.

• In Q1 2026, Operating Leases fell 22.83% year-over-year to $33.7 million; the TTM figure through Mar 2026 stood at $33.7 million (down 22.83% YoY), while the FY2025 annual figure was $36.2 million, down 18.97% from the prior year.
• Operating Leases was $33.7 million for Q1 2026 at Pacira BioSciences, down from $36.2 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $77.7 million in Q1 2022 to a low of $33.7 million in Q1 2026.
• Historically, Operating Leases has averaged $55.5 million across 5 years, with a median of $57.1 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Operating Leases advanced 11.57% in 2022, then slumped 30.36% in 2025.
• A 5-year view of Operating Leases shows it stood at $64.8 million in 2022, then fell by 15.43% to $54.8 million in 2023, then decreased by 18.54% to $44.6 million in 2024, then slipped by 18.97% to $36.2 million in 2025, then retreated by 6.83% to $33.7 million in 2026.
• The last three Operating Leases figures came in at $33.7 million (Q1 2026), $36.2 million (Q4 2025), and $48.6 million (Q3 2025), per Business Quant data.